Outsmarting the Heart: Device Therapy Targeting the Neurohormonal Pathway in Heart Failure Patients

Barostim, a novel device therapy, complements GDMT by targeting neurohormonal pathways in heart failure. Here, experts discuss patient selection, outcomes, and strategies for integrating Barostim into care for patients with Class II/III HFrEF.